Analysis of METTL3 mRNA expression alterations revealed that ~32% of adenocarcinoma samples possessed altered METTL3 mRNA expression, with 79/498 cases (~15%) having low METTL3 expression, and 85/498 cases (~17%) possessing elevated METTL3. Here, METTL3 is linked to adenocarcinoma.